Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome1  by Shearer, Gregory C. et al.
Kidney International, Vol. 59 (2001), pp. 179–189
Hypoalbuminemia and proteinuria contribute separately to
reduced lipoprotein catabolism in the nephrotic syndrome1
GREGORY C. SHEARER, FRAZIER T. STEVENSON, DAVID N. ATKINSON, HARDIN JONES, JR.,
ILONA STAPRANS, and GEORGE A. KAYSEN
Division of Nephrology, Department of Medicine, UC Davis, Davis; Department of Veterans Affairs Northern California
Health Care System, Mather; and the Department of Surgery, Department of Veterans Affairs Medical Center,
San Francisco, California, USA
quence of reduced serum albumin concentration, and (2) aHypoalbuminemia and proteinuria contribute separately to re-
defect in VLDL binding to endothelial-bound LpL. This latterduced lipoprotein catabolism in the nephrotic syndrome.
defect occurs only in the presence of proteinuria and is con-Background. Hypertriglyceridemia is a result of reduced tri-
ferred by HDL.glyceride (TG)-rich lipoprotein (TRL) catabolism and occurs
in rats with nephrotic syndrome (NS) and in Nagase analbumi-
nemic rats (NARs). While the heparin-releasable lipoprotein
lipase (LpL) pool in NAR and in NS is similar, TG levels are While hyperlipidemia is a common complication ofsignificantly greater in NS, suggesting that factors other than
the nephrotic syndrome (NS), it is unclear whether it isreduced LpL alone act in NS but not in NARs. Furthermore,
a direct consequence of proteinuria or whether it arisesclearance of chylomicrons (CM) and very low-density lipopro-
tein (VLDL) is normal in vivo in NAR despite low LpL levels. secondarily from other effects of proteinuria, such as
We tested the hypotheses that impaired binding of VLDL and reduced plasma oncotic pressure (p) or hypoalbumi-
impaired VLDL–high density lipoprotein (HDL) interactions nemia. Hyperlipidemia occurs in both the NS and thecontribute to hyperlipidemia in NS.
condition of hereditary analbuminemia in both humansMethods. TG and apoB secretion was measured using Triton
and rats [1–5]. Hereditary analbuminemia occurs in theWR 1339. Clearance of CMs by perfused hearts from NS and
NAR was determined. Binding of VLDL from control, NS and Nagase analbuminemic rats (NARs), which serve as
NAR to rat aortic endothelial cells (RAECs) was measured models of hypertriglyceridemia lacking proteinuria but
prior to and following incubation with HDL from NS, NARs, having other aspects of the NS, such as hypoalbuminemiaand control. ApoE, protein, and TG content was determined.
and reducedp. Although serum albumin concentrationResults. TG levels were greatest in NS (516 6 95 mg/dL),
is nearly undetectable in NAR, lipid levels, while in-intermediate in NAR (193 6 20), and least in control (97 6
16, P 5 0.05), while in contrast, TG secretion was least in NS creased in comparison to normal animals or subjects, are
(178 6 33 mg/dL/hour) versus 212 6 17 in NAR and 294 6 generally much lower than in the NS. Our past data have
15 in control (P , 0.001 vs. NS). Clearance of CMs by NS and suggested that this is due, at least in part, to a clearanceNAR hearts was the same and significantly reduced versus
defect of triglyceride (TG)-rich lipoproteins (TRL) [6].control (P , 0.005). Binding of NS-VLDL to endothelial cells
Triglyceride-rich lipoproteins are catabolized largelywas reduced, while NAR-VLDL binding was increased versus
control (P , 0.001). Incubation of NS-VLDL with control or by lipoprotein lipase (LpL), which in its active form
NAR HDL increased VLDL binding compared with binding is tethered to the heparan sulfate proteoglycan on the
following incubation with NS HDL (P , 0.001). vascular endothelium. This metabolically important LpLConclusion. Increased TG levels in both NS and NAR are
pool is released upon administration of heparin [7]. Pre-the result of decreased TRL clearance. TG levels are greater
vious investigations have thus focused on this pool andin NS because of the presence of a combined defect: (1) a
decrease in endothelial-bound LpL that occurs as a conse- have shown that it is reduced in NS. Interestingly, this
endothelial LpL pool in NAR is reduced to the same
extent as in NS [6], yet TG levels are significantly greater
1 See Editorial by O’Donnell, p. 380. in NS. This observation suggests that factors in addition
to the amount of endothelial LpL may play an importantKey words: very low-density lipoprotein, chylomicron, apolipoprotein
E, triglyceride, proteinuria. role in regulating lipid levels in the NS.
Two potential causes of increased serum TG are ap-Received for publication November 17, 1999
parent. One is that TRL synthesis, in this case very low-and in revised form June 13, 2000
Accepted for publication July 25, 2000 density lipoprotein (VLDL), might be greater in the NS
than in NAR. Second, factors in addition to the amountÓ 2001 by the International Society of Nephrology
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of endothelial-bound LpL might play a role in regulating sequential flotation according to the method described
by Schumaker and Puppione [12]. Because we found thatTRL catabolism. The latter is suggested by Furukawa et
al, who observed that lipolysis of VLDL by LpL in vitro the VLDL fraction contained small amounts of albumin,
VLDL to be iodinated was subject to additional centrifu-was less when the VLDL was derived from nephrotic
rats in comparison to controls [8]. These observations gation. We used the centrifugal flotation of particles as
described by Gianturco and Bradley [13]. Samples ofsuggested that abnormalities intrinsic to the lipoproteins
might play a role in reducing their rate of clearance. VLDL before and after this flotation step were scanned
using a STORM imager (Molecular Dynamics, Sunny-We designed experiments to explore changes in in vivo
clearance, binding properties, and structure of nephrotic vale, CA, USA) and staining with the fluorescent marker
SYPRO orange. This stain was selected because of itsTRL and to explore how LpL and HDL modulate TRL
binding and clearance. uniform staining regardless of protein structure. The im-
ages were analyzed using ImageQuant software (Molec-
ular Dynamics). The faint albumin band (66 kD) de-
METHODS
tected in the primary VLDL prep was not detected in
Animals VLDL that was labeled. VLDLs were stored under he-
lium and were used within 14 days of collection.Studies were approved by the Animal Review Com-
mittee of the University of California (Davis, CA, USA). The ApoE content was determined by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)Rats were all male. Control animals and animals that
were made nephrotic were of the Sprague-Dawley strain, of VLDL on 4 to 15% gradient gels and subsequent
STORM analysis. A standard curve for quantitation us-the strain from which NAR were bred, and were pur-
chased from Simenson Farms (Hayward, CA, USA). ing bovine serum albumin was generated for each gel.
ApoE was positively identified by Western blot analysisNARs were obtained from our own breeding colony
maintained at UC Davis (Davis, CA, USA). These ani- using antibodies for human apoE (Dako, Glostrup, Den-
mark). Both apoE content and apoA1 content were simi-mals were derived from animals obtained from Jaap Joles
(Utrecht, The Netherlands) and have been bred as de- larly determined in HDL.
scribed previously [9]. All rats were kept in 24-hour light/
Preparation of chylomicronsdark rooms and fed ad libitum.
Nephrotic syndrome was induced in two models. Radiolabeled chylomicrons (CMs) were obtained by
the method of Bollman, Cain, and Grindlay [14]. RatsAdriamycin-induced NS, NS-ADR, was produced by an
intravenous injection of 5 mg/kg adriamycin (Adriamy- were gavage-fed a 2 mL emulsified preparation of corn
oil/milk (1:2) sonicated with glycerol [9,10-3H] trioleatecin RDF; Pharmacia & Upjohn, Milan, Italy) at five
weeks of age. Urinary albumin excretion was measured (0.15 mCi). The thoracic duct was cannulated, and chyle
was collected on ice for 18 hours. CMs were isolated bysix weeks after injection with adriamycin and rats with
both TG levels .450 mg/dL and albuminuria of .800 layering the chyle under 0.15 mol/L NaCl and flotation
on a SW-40ti rotor (Beckman Instruments, Palo Alto,mg/day were selected. Alternatively, the NS was induced
by an intraperitoneal injection of FX1-A antiserum ob- CA, USA) at 5 3 106 g · min at 168C for 18 hours.
tained from William Couser (University of Washington,
Purification of LpLSeattle, WA, USA) to produce Heymann nephritis, NS-
HN, as described previously [10]. FX1-A antibody pro- Lipoprotein lipase was purified using the methods of
Liu and Severson [15]. Fractions with an optical densityduces either complete NS or none at all, and a simple
test for the presence of urinary protein was sufficient of $0.200 AU at 280 nm were subsequently analyzed
by SDS-PAGE, and fractions containing a single darklycriteria for selection. Rats were anesthetized with an intra-
peritoneal injection of 65 mg/kg (control) or 20 mg/kg (NS, staining band at 55 kD were pooled.
NAR) sodium pentobarbital and were exsanguinated by
Cellsaortic puncture. All protocols were approved by the Ani-
mal Resources Service committee at UC Davis. A primary culture of rat aortic endothelial cells
(RAEC) was obtained by the method of McGuire and
Isolation and protein content of lipoproteins Orkin from a control rat [16]. The thoracic aorta was
gently removed, cleaned, and sliced into 2 to 3 mm sec-Very low-density lipoproteins and high-density lipo-
proteins (HDLs) were used for several protocols. In each tions under sterile conditions. These sections were laid
onto a layer of Matrigel (Becton-Dickinson, Bedford,case, plasma was handled using the method recom-
mended by Edelstein and Scanu [11]. Blood was col- MA, USA) in a 24-well cluster plate that had been pre-
conditioned for one hour with E-STIM endothelial celllected in ethylenediaminetetraacetic acid (EDTA) and
centrifuged for 10 minutes at 3000 3 g to remove red growth medium (Becton-Dickinson) supplemented with
epidermal growth factor and endothelial cell growth sup-blood cells. VLDL and HDL were then isolated using
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plement. After eight days of growth, the explants were immunoelectrophoresis as described by Oudin using
antihuman apoB (Boehringer Mannheim, Mannheim,removed, and the remaining cells were allowed to grow
for an additional week, whereupon they exhibited cob- Germany) [19]. A pool of five fasted, control male rats
provided a standard, and apoB levels were measuredblestone morphology typical of endothelial cells. The
cells were removed from the Matrigel by incubation with relative to the pool.
2% dispase for 30 minutes and were passed into a 25 cm2
Experiment 2: Heart chylomicron clearancetissue culture flask coated with collagen I. The cells there-
after were grown on collagen I under the aforementioned To determine whether the clearance defect of TRLs
is due to changes in the endothelium or to changes intrin-growth supplement. Because of the presence of smooth
muscle cells, the cells were trypsinized and diluted for sic to the lipoprotein particles (lipoprotein structure or
lipoprotein–lipoprotein interaction), we measured TRLsingle-cell cloning by passage into 48-well cluster plates.
A subclone staining negative for a-smooth muscle actin clearance by isolated perfused hearts. CMs were ob-
tained from control animals, and controlled (and identi-and positive for uptake of acetylated DiI-LDL was se-
lected for further expansion. cal) albumin concentration was used in the perfusate.
Thus, the only differences were the sources of the heart.To help show that binding differences are intrinsic to
the lipoprotein, bovine aortic endothelial cells (BAECs), We used five control, six NS-HN, and four NAR. Hearts
were excised and retrograde perfused according toa generous gift from Martha O’Donnel (University of
California, Davis, CA, USA), were also used. These cells method of Langendorff, as described by Fielding using
Krebs buffer [20]. No heparin was used, and hearts werewere cultured in the manner as the cells derived from
rats. attached to the perfusion apparatus within one minute
after excision. After five minutes of washout, labeled
Radiolabeling of VLDL CM were added to the pool to make the initial recirculat-
ing TG concentration 55 mg/mL. Samples were takenVery low-density lipoproteins were radiolabeled ac-
cording to the method of McFarlane as modified by at five-minute intervals. Triolein was extracted by the
method of Trout, Estes, and Freidberg [21]. The extractsHelmkamp, Contreras, and Bale [17]. Labeled VLDL
were dialyzed exhaustively (1,000 MWCO) with phos- were counted in a liquid scintillation counter for 10 min-
utes. CM clearance curves were calculated by linear re-phate-buffered saline (PBS), pH 7.4, until the TCA pre-
cipitable counts were greater than 95% of total. To deter- gression using the method of least squares on the natural
log of percentage remaining counts versus elapsed time.mine the labeling of individual apolipoproteins, labeled
VLDL were then analyzed using SDS-PAGE followed The half-life of disappearance (t1/2) was determined as
ln(2)/b, where b is the determined rate constant.by imaging of the gel with the STORM imaging plate.
The apolipoproteins labeled approximately in propor-
Experiment 3: VLDL bindingtion to their relative abundance in the VLDL. The low
molecular weight apoproteins, E, CII, CIII contained To determine the potential contribution of alterations
TRL structure to reduced clearance, we measured bind-the most 125I label in VLDL purified from each source.
ing of TRL to identical endothelial surfaces. Twelve con-
Protein and lipids trol rats, six NS-ADR, and four NAR were used to gener-
ate VLDL pools. Six control and two NS-HN rats wereTotal proteins were measured using a bicinchoninic
acid protein assay (Pierce, Rockford, IL, USA). TGs used to compare binding of NS-HN VLDL and control
VLDL. Rats were exsanguinated while under anesthesia,were measured using a GPO-trinder test kit obtained
from Sigma (St. Louis, MO, USA). and the resulting plasma was then collected and pooled.
For binding studies, RAECs at passages 9 to 10 were
Experiment 1: Measurement of VLDL secretion plated into 48-well plates, and experiments were per-
formed one to two days after reaching confluence. TheseThe net rate of VLDL and apoB secretion was mea-
sured by blocking uptake with Triton WR 1339 as de- same cells did not incorporate 3H-thymidine after 48-
hour exposure to rest medium [Dulbecco’s modified Ea-scribed by Feingold et al [18]. In this protocol, we used
five control, five NAR, and three NS-ADR. Animals gle’s medium (DMEM) 1 5% fetal bovine serum (FBS)]
at passage 11. Alternatively, BAECs at passages 6 towere fasted overnight. Uptake of TRL was blocked by
an intravenous injection of 600 mg/kg triton WR 1339. 7 were used. Media containing DMEM, 25 mmol/L
HEPES, pH 7.4, lipoprotein deficient FBS and 5 mg/mLSerum (100 mL) was collected by tail bleed at time zero,
prior to Triton administration, and then at 30-minute LpL was used to prepared appropriate concentrations
of labeled and unlabeled VLDL. To solutions containingintervals for two hours. Animals were lightly restrained
and not sedated. The rate of VLDL secretion is the 0.5 mg/mL protein-labeled VLDL, unlabeled VLDL were
added to achieve total VLDL protein concentrations ofincrease of serum TG and apoB levels (slopes) following
injection of Triton WR 1339. ApoB was measured using between 0.5 and 20 mg/mL. Wells containing a total of
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300 mg/mL VLDL protein were used to assess nonspecific RESULTS
binding. Plates were removed from incubators and al- TG and apoB secretion
lowed to cool on ice for 30 minutes; 0.125 mL of VLDL
Initial serum TG in nephrotic rats was 5.6-fold greatermedia was added to wells, and each concentration was
than controls (control 5 97.0 6 15.6; NS-ADR 5 516.3 6assayed in triplicate. Plates were gently shaken for five
94.7 mg/dL; P , 0.05), while serum TG in NAR, thehours at 48C. The cells were then rinsed three times with
nonproteinuric model, was elevated only twofold versusPBS 1 2 mg/mL albumin at 48C, incubated two times
control (control 5 97.0 6 15.6; NAR 5 193.4 6 20.1for 10 minutes with PBS 1 2 mg/mL albumin at 48C,
mg/dL; P , 0.05). TG secretion did not increase in eitherand rinsed two times with PBS at 48C. Finally, the cells
nephrotic nor NAR compared with control (Fig. 1A).were dissolved in 0.25 mL 0.1 mol/L NaOH and counted
Indeed, TG secretion was significantly reduced in ne-on a Packard gamma counter.
phrotic and tended to be reduced in NAR (control 5Very low-density lipoprotein was incubated with HDL
294 6 15, NAR 5 212 6 17, NS-ADR 5 178 6 33 mg/dL ·according to the method of Furukawa et al [8]. Three
hr21, P , 0.001).hundred fifty milligrams of VLDL protein were incu-
Initial serum apoB levels in nephrotic rats were 1.6-bated with HDL at a ratio of 0.7 mg HDL protein to
fold greater than in controls, while apoB was increased1.0 mg VLDL TG. The solution was then diluted with
by 1.1-fold in NAR (control 5 97.6 6 1.6, NAR 5PBS to 1.25 mL and incubated for two hours at 378C. The
111.0 6 3.6, NS-ADR 5 152.0 6 8.0% control, P , 0.05;VLDL were then re-isolated as described previously.
Fig. 1B). Secretion of apoB in nephrotic was increasedWe measured the dose response of LpL binding activa-
versus both control and NAR (control 5 198.4 6 12.5,tion at four VLDL concentrations: 0.5, 2.5, 7.5, and 15 mg
NAR 5 228.1 6 3.5, NS-ADR 5 287.2 6 31.4% control ·protein/mL. At each VLDL concentration, the amount
h21, P , 0.05); however, apoB secretion in NAR wasof LpL coincubated with VLDL was varied from 0.05
not increased (Fig. 1B).to 5 mg/mL.
Clearance of CM by isolated perfused heartsExperiment 4: Effect of control HDL on CM
The rate constant of CM clearance, b, was reducedclearance in nephrotic rats
significantly in hearts from nephrotic and analbuminemicWe finally measured the effect prior infusion of control
animals compared with controls (control 5 20.047 6HDL had on clearance of TGs in CMs in nephrotic rats.
0.002; NAR 5 20.023 6 0.003; NS-HN 5 20.021 6Because of the difficulty in obtaining TG-labeled VLDL,
0.001 ln(% counts remaining) · min21, P , 0.005), butwe used CMs as a substitute. We have previously estab-
there was no significant difference between clearance bylished that clearance of [9,10-3H]-trioleate labeled CM
hearts obtained from NAR and NS-HN (Fig. 2).from control rats is not different from [3H]-trioleate la-
beled VLDL from control rats. Furthermore, the clear-
VLDL bindingance defect of VLDL and CM in nephrotic Sprague-
We tested whether the enhancement of binding byDawley and nephrotic NAR was similar [6]. Thus, CMs
LpL was dependent on the source of VLDL. VLDLwere used as a surrogate for VLDL. Four control and
concentration was held constant at 2.5, 7.5, or 15.0 mg/mLeight HN rats were used. Immediately prior to CM injec-
total protein, while the concentration of LpL wastion, 7.5 mg HDL were administered to 2 HN. Blood
changed from 0.05 to 5.0 mg/mL, and the percentage(0.25 mL) was obtained at two- to five-minute intervals
maximal binding (at 5 mg/mL) was compared. No re-for 25 minutes by tail bleed. CM clearance was measured
markable differences in the response of VLDL bindingby the disappearance of [3H]-labeled CMs after intrave-
to increasing amounts of LpL were observed eithernous injection as previously described in experiment 2.
across VLDL concentrations or between VLDL source
Statistical analysis (data not shown).
However, binding of VLDL from nephrotic rats wasDifferences in binding were determined by two-way
reduced compared with VLDL from control rats (P ,analysis of variance using version 2.03 of Sigma Stat soft-
0.001), while binding of VLDL from NAR was actuallyware. For analysis of clearance, b, or the rate constant,
increased, as determined by two-way analysis of variancewas used to determine statistical differences between
(P , 0.001), and this effect was not dependent on thegroups, since it is normally distributed and t1/2 is not.
binding surface, as it was present on binding to RAECHowever, since t1/2 is more easily familiar, the figures
or BAEC (Fig. 3). NS-HN VLDL binding was reducedinclude the half-life as determined by transformation of
at least as much as NS-ADR compared with controlthe mean b. Linear regression and nonlinear regression
VLDL binding (P , 0.001; Fig. 4). Prior incubation ofanalysis were performed using version 2.01 of Prism soft-
NS-ADR VLDL with HDL from either NAR or controlware. Differences of P , 0.05 were considered signifi-
cant. rats increased binding compared with prior incubation
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Fig. 1. Plasma very-low density lipoprotein
(VLDL) secretion rates in control (j), Nagase
analbuminemic rats (NAR; d), and adriamy-
cin-induced nephrotic syndrome (NS-ADR;
m). Mean VLDL triglyceride (TG) secretion
rates were measured from TG concentration
in serum from tail blood of fasted rats follow-
ing injection of 600 mg/kg Triton WR 1339.
(A) Accumulation of serum TG. There are sig-
nificant differences in the initial TG. The inset
represents the average rate of TG accumula-
tion. (B) The accumulation of apoB as a per-
cent of control apoB levels. There are signifi-
cant differences in initial apoB levels. The
inset represents the average rate of apoB accu-
mulation. Error bars represent SEM. †P ,
0.05 vs. control. ‡P , 0.05 vs. NAR.
with NS-ADR HDL (P , 0.001; Fig. 5A). Similarly, in and 0.14 (NS-HN), compared with ratios of 0.23 and 0.31
obtained for HDL in control or NAR animals.VLDL from control rats, prior incubation with control
HDL also increased binding compared with NS-ADR
Infusion of control HDL corrects defective clearanceHDL (P , 0.001; Fig. 5B). There was no effect of binding
The rate constant, b, of CM clearance in nephrotic ratssurface (Fig. 5C).
was significantly lower than in control rats (NS-HN 5
HDL and VLDL composition 20.016 6 0.003; control 5 20.098 6 0.006 ln (% counts
remaining) · min21, P , 0.001; Fig. 6). Nephrotic ratsWe next measured relative composition of apoE and
infused with control HDL prior to CM injection had aapoA1 in isolated particles by SDS-PAGE of VLDL and
significantly greater CM clearance than nephrotic ratsHDL followed by staining of total proteins (Table 1).
without HDL infusion (NS-HN 1 HDL 5 20.037 6The TG to protein ratio was 2.3-fold greater in pooled
0.001; NS-HN 5 20.016 6 0.003 ln (% counts remaining) ·VLDL from NS-ADR rats and twofold greater in NS-
min21, P , 0.005).HN rats, but was virtually unchanged in NAR VLDL.
While the pool of VLDL from NAR rats was apoE
DISCUSSIONenriched per mole of TG, the ratio of apoE to TG was
the same among the control and nephrotic VLDL pools. Our study shows that increased TG synthesis does not
High-density lipoprotein from NS was poor in apoE contribute to increased TG levels in either NS or in NAR.
Indeed, TG synthesis is actually reduced in NS-ADRrelative to apoA-1, with a molar ratio of 0.11 (NS-ADR)
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Fig. 2. Clearance of chylomicrons (CMs) by hearts from control (j;
t1/2 5 14.8 min), Heymann nephritis-nephrotic syndrome (NS-HN) (m;
t1/2 5 30.2 min†), and Nagase analbuminemic rat (NAR); (d; t1/2 5 33.2
min†). Removal of triglycerides (TG) from CM by isolated perfused
hearts. CM labeled with [3H]-trioleate was added to recirculating Krebs
buffer to make a final TG concentration of 55 mg/mL. Error bars
represent SEM. Clearance is reported here in t1/2, but statistical differ-
ences were determined using the rate constant, b (Methods section).
†P , 0.05 vs. control. Note log scale of y axis.
and tends to be reduced in NAR. While apoB synthesis
is increased, the magnitude of increase is quite small in
Fig. 3. Binding of VLDL from control (j), NAR (d†), and NS-ADRcomparison to the increased levels of this apolipoprotein
(m†). Specific binding of VLDL to aortic endothelial cells was measured
serum. Thus, decreased catabolism is primarily responsi- after five hours using 125I labeled VLDL. (A) Binding to rat aortic
endothelial cells (RAECs). (B) Binding to bovine aortic endothelialble for the increased levels of apoB as well. Similarly,
cells (BAECs). Error bars represent SEM. †P , 0.05 vs. VLDL fromin nephrotic patients, plasma TG levels are determined
control rats.
by the fractional clearance of VLDL apoB-100, and not
its rate of synthesis [22].
Thus, factors contributing to a reduction in serum TRL
catabolism determine serum TG levels in the NS. Clear- Clearly, one important mechanism responsible for a
ance of TRL TG is mediated in two ways. First, circulat- defect in lipoprotein catabolism is a reduction in endo-
ing TRLs bind to either LpL, to their cognate receptors, thelial bound LpL. This is of secondary importance in the
or to both. Following that binding, lipolysis-mediated intact (non-nephrotic) animal, although the reduction in
catabolism takes place at the vascular endothelium [23], LpL remains evident in isolated hearts. A reduction in
releasing free fatty acids for uptake by parenchymal tis- endothelial LpL has been found both in nephrotic rats
sue. This process is dependent on delivery and binding [10, 28–30] and patients with the NS [31]. This depletion
of LpL to endothelial heparan sulfate [24] and on TRL is accompanied by reduced CM lipolysis in vitro [32].
binding to the LpL-heparan sulfate complex [25]. LpL is This is not the case in NAR. Although endothelial LpL
a mediator of substrate binding for each of the LDL re- is reduced to a similar extent in analbuminemic rats,
ceptor family receptors (the LDL, VLDL, and LDL re- the clearance defect in this strain is quite minimal [6].
lated protein receptors) and, thus, in addition to its lipo- Furthermore, a reduction in heparin-releasable LpL in
lytic effects, is also important in lipoprotein binding the NS is also not a universal finding [33], suggesting
[25, 26]. VLDL and CM can be cleared following binding that reduction in this pool is neither necessary nor suffi-
via their apoB or apoE moieties or via heparan sulfate cient to produce a profound reduction in lipoprotein
catabolism. Since NS are also hepatic lipase deplete [34]alone [26, 27]. Thus, lipolysis and binding both represent
potential lesions in TG catabolism in NS. and hepatic lipase also mediates lipoprotein binding, not
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Fig. 4. Binding of VLDL from control (j) and NS-HN (m†) Specific
binding of VLDL to BAECs was measured after five hours using
125I-labeled VLDL. Error bars represent SEM. †P , 0.05 vs. VLDL
from control rats.
only is there no hepatic lipase-mediated lipolytic com-
pensation in NS, but VLDL binding to hepatocytes is
likely reduced as well.
Our previous data have shown a marked difference
in CM clearance in NAR versus NS, despite similar endo-
thelial LpL levels, suggesting that additional factors may
contribute to reduced TRL clearance. Such factors could
be a result of changes in lipoprotein receptor type, recep-
tor number, or in the composition of TRL. Thus, there
exists a potential defect associated with the endothelium,
either LpL and/or receptor type/number, and a defect
associated with the plasma compartment. Liang and Vaz-
iri report reduced VLDL receptor levels in nephrotic
animals, suggesting the reduced endothelial binding of
lipoproteins due to reduced receptor number contribute
to elevated serum TG [35]. To determine whether there
was an additional endothelial defect independent of se-
rum components, we perfused hearts from control, NAR
and NS-HN with control CM and found that the clear-
ance by NAR and NS-HN was nearly identical. This
suggested that the difference in catabolism in vivo is a
consequence of altered TRL structure, and lipoprotein-
LpL, or lipoprotein–lipoprotein interactions, although
we cannot exclude the presence of a nonlipoprotein cir-
culating factor that may play a role.
We tested the hypothesis that an altered TRL struc- Fig. 5. Binding of HDL-treated VLDL. HDL protein (0.7 mg) was
incubated with 1.0 mg VLDL TG for two hours, and then VLDLs wereture contributes to the catabolic defect more directly by
reisolated. (A) Binding to RAEC of VLDL from NS-ADR incubatedassessing VLDL binding to cultured aortic endothelial with HDL from control (r‡), NAR (d‡), and NS-ADR (m) rats. (B)
cells. NAR VLDL binding was increased at all concen- Binding to RAEC of VLDL from control rats incubated with HDL
from control (r‡) and NS-ADR (d). (C) Controls for binding surfacetrations compared with control, while NS-ADR VLDL
and represents binding to BAEC of VLDL from NS-ADR incubatedwas decreased (Fig. 3). This defect persists regardless of with specific binding of VLDL to aortic endothelial cells was after five
the binding surface used and regardless of the model of hours measured using 125I-labeled VLDL. Error bars represent SEM.
‡P , 0.05 vs. VLDL incubated with nephrotic HDL.NS. The binding differences may be explained by marked
differences in lipoprotein composition in NAR versus
both models of NS. In NS, since TG synthesis is reduced
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Table 1. Lipoprotein content
VLDL HDL
TG/protein mmol TG/ ApoE/apoA1
Ratio mg/mg nmol apoE mol/mol
Control 1.11 1.72 0.34
NAR 0.92 3.91 0.23
NS-ADR 2.57 1.56 0.15
NS-HN 2.27 2.01 0.14
Abbreviations are: VLDL, very-low density lipoprotein; HDL, high density
lipoprotein; TG, triglycerides; apo, apolipoprotein; NAR, Nagase analbuminemic
rat; NS, nephrotic syndrome; HN, Heymann nephritis.
and apoB synthesis is increased, one would expect a
particle that is relatively poor in lipids and rich in protein
to be found in peripheral blood. This is not what was
observed: Analysis of VLDL fractions instead showed
a TG-enriched particle. In contrast, the NAR particle
was apoE rich, but had TG content similar to control.
Fig. 6. Effect of control HDL on CM clearance in rats with HeymannThese effects of the NS were not model dependent, as
nephritis. Symbols are: (m) untreated NS-HN, t1/2 5 43.0 min†; (n)they were seen in both Heymann and adriamycin nephri- NS-HN 1 control HDL, t1/2 5 18.6 min‡; (j) control, t1/2 5 7.1 min.
tis. Because the NAR VLDL had diametrically different CM labeled with [3H]-trioleate was injected intravenously via the tail
vein, and blood was sampled at selected intervals. To determine thestructure and binding ability, these VLDL changes seen
effect of control HDL on clearance in NS-HN rats, 7.5 mg of controlin NS-ADR VLDL must represent an effect of protein- HDL protein were administered as a bolus to NS-HN rats immediately
uria rather than of hypoalbuminemia. prior to CM injection. Error bars represent SEM. Clearance is reported
here in t1/2, but statistical differences were determined using the rateIncreased binding, as seen in the NAR, may represent
constant, b (see Methods section). †P , 0.05 vs. control; ‡P , 0.05 vs.a normal compensatory mechanism to improve TG clear- control and NS-HN. Note log scale of y axis.
ance in the presence of reduced endothelial LpL. This
mechanism is disordered in the presence of proteinuria.
ApoE is a ligand for the LDL receptor family receptors
that mediate this process [36]. However, apoE assumes
but not nephrotic animals corrected defective lipolysistwo conformations with respect to binding, a low- and
of VLDL from nephrotic rats, suggesting that HDL maya high-affinity conformation [37]. The high-affinity con-
mediate differences in the rate of VLDL lipolysis in vivoformation is dependent on the lipid content of the lipo-
[8]. In our study, HDL from either control or NARprotein [38], and Gianturco et al have shown that TRL
stimulated VLDL binding to a greater extent than HDLfrom hypertriglyceridemic patients lacks the high-affinity
from NS-ADR. We also found reduced levels of apoEapoE [39]. It is likely that the apoE in VLDL from
in HDL from NS-ADR but not in HDL from NAR.nephrotic rats is also lacking in high-affinity apoE since
HDL contributes the majority of apoE and apoC tothese VLDL are also TG rich. Thus, the binding of VLDL
VLDL and CM.from nephrotic rats would be expected to exhibit reduced
There are no previously published data on the compo-endothelial binding despite otherwise normal apoE/TG
sition of HDL in normal rats with NS. However, Hiranoratios. NAR VLDL are not only rich in apoE, but they
et al, in a study on Dahl salt-sensitive rats with the NS,also have similar lipid content as control VLDL. Thus,
found reduced apoE/A1 ratios in HDL [28]. ReducedNAR VLDL are more likely to have apoE in the high-
ability of HDL to properly donate apoproteins in suffi-affinity conformation. These properties of NAR VLDL
cient quantities necessary for efficient TRL catabolismthus suggest a possible mechanism for their increased
provides a mechanism for Furukawa’s observation. Whilebinding over even control VLDL. It is likely that protein-
the HDL level is actually increased in both NS and NARuria disrupts this compensatory mechanism in NS since
[9], there is less apoE in NS HDL, thus reducing HDLhighly contrasting results are obtained in NAR versus
transfer of apoE to VLDL. Indeed, the presence ofnephrotic rats. The mechanism of the phenomenon we
apoE-depleted HDL may contribute more to defectivereport here will require further study.
TRL catabolism than improve it, as apoE-deplete HDLDifferences in HDL composition mediate changes in
would more likely be an apoE sink rather than a source.VLDL composition. Furukawa et al found that VLDL
Marked alteration in HDL composition may be due toisolated from nephrotic rats was hydrolyzed at a reduced
rate by LpL in an in vitro system. HDL from control down-regulation of SR-B1, the HDL receptor responsi-
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Fig. 7. Proposed model of triglyceride (TG)
clearance defects in nephrotic and analbumi-
nemic rats describing possible lesions of tri-
glyceride-rich lipoprotein (TRL) catabolism
in Nagase analbuminemic rats (NAR) and ne-
phrotic syndrome (NS).
ble for internalization of HDL cholesterol [40]. Down- apoA1 content) in NAR are increased about 1.7-fold
[9], and total HDL apoE in NAR is also greater thanregulated SR-B1 may also cause changes in HDL lipid
content further decreasing the ability of NS HDL to control. We propose that NAR HDLs maintain the abil-
ity to effectively donate apoE to VLDL and even en-enhance VLDL binding; however, this requires further
study. hance apoE to TG content (Fig. 7B). Clearly, NAR HDL
in vitro has the same effect as does control HDL inIn contrast, the normal apoE content of NAR HDL
combined with the elevated HDL levels may result in eliminating the binding defect that characterizes ne-
phrotic VLDL. The TG to apoE ratio is increased inincreased transfer of apoE to VLDL, thus explaining its
increased ability to bind. This may explain why NARs NAR VLDL. Since apoE is found on only the surface
of these particles, the opportunity for interaction withhave at least normal binding and nearly normal clearance
of VLDL, while binding is reduced in NS despite the receptors is enhanced beyond what would be expected
from the increased molar concentration alone.elevated HDL levels.
Finally, control HDL improves clearance of VLDL in Like NAR, NS rats have two- to threefold elevated
levels of HDL, but unlike NAR, they have a reducedthe nephrotic rat, confirming that this effect of HDL
persists in vivo. Levels of HDL are increased in nephrotic apoE per apoA1 (Table 1), suggesting that total HDL
apoE is essentially unchanged [9]. Thus, each NS HDLrats, and this effect of control HDL was observed despite
that increase, suggesting that nephrotic HDL is unable particle is apoE poor (Fig. 7C). NS HDLs donate apoE
to NS-VLDLs that are greatly TG enriched, and thus,to mediate increased TG catabolism even in excess, con-
sistent with our hypothesis. apoE remains in its low-affinity conformation. The result
is poor endothelial binding of VLDL, amplifying theBased on the experimental results, we propose the
following model of TRL removal in the NS in contrast negative effects of endothelial LpL depletion.
Thus, hypertriglyceridemia in the nephrotic syndrometo analbuminemia outlined in Figure 7. In comparison
to control, NAR VLDLs are apoE rich. Although each is primarily a result of decreased catabolism, confirming
the observation of Yoshino et al that it is not due toNAR HDL particle is less apoE rich than are control
HDL particles, total levels of HDL (as measured by increased VLDL secretion [41]. In addition to the de-
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